NGS-Based RNA-Sequencing Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
NGS-Based RNA-Sequencing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product and Services (RNA Sequencing Platforms and Consumables, Sample Preparation Products, RNA Sequencing Services, Data Analysis, Storage and Management), By Technology (Sequencing By Synthesis, Ion Semiconductor Sequencing, Single-Molecule Real-Time Sequencing, Nanopore Sequencing), By Application (Expression Profiling Analysis, Small RNA Sequencing, De Novo Transcriptome Assembly, Variant Calling and Transcriptome Epigenetics), By End User (Research and Academia, Hospitals and Clinics, Pharmaceutical and Biotechnology Companies, Others), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The Global NGS-Based RNA-Sequencing Market is projected to expand from USD 3.18 Billion in 2025 to USD 4.75 Billion by 2031, reflecting a compound annual growth rate of 6.92%. This high-throughput genomic technology is utilized to examine the transcriptome, facilitating precise gene expression quantification and the identification of new RNA variants. The market is primarily propelled by the shift toward personalized medicine and the urgent requirement for transcriptomic data in drug discovery, specifically for rare diseases and oncology. This demand is intensified by the creation of advanced therapeutics necessitating strict genomic validation; for instance, the Pharmaceutical Research and Manufacturers of America reported in 2024 that the industry pipeline contained 289 novel cell and gene therapies, highlighting the sector's increasing reliance on sophisticated sequencing tools.
Despite these growth drivers, the market encounters a significant obstacle regarding bioinformatics analysis and data management. The immense datasets produced by modern sequencing platforms demand extensive computational infrastructure and specialized expertise for accurate interpretation. This computational bottleneck frequently delays time-to-result and raises operational expenses, which can hinder broader implementation in clinical environments where streamlined and rapid diagnostics are crucial.
Market Driver
A primary catalyst for growth is the surging demand for single-cell RNA sequencing, as researchers increasingly require granular resolution to comprehend cellular heterogeneity. Unlike bulk sequencing, which averages gene expression across a sample, single-cell platforms enable the distinct profiling of individual cells, a capability vital for mapping complex tissue microenvironments in immunology and oncology. This technological shift is reflected in the financial performance of specialized providers; according to 10x Genomics' 'Full Year 2023 Financial Results' in February 2024, the company achieved $618.7 million in revenue, a 20% increase from the prior year, largely driven by the adoption of their spatial and single-cell transcriptomics solutions. This trajectory suggests a fundamental move in experimental design toward high-resolution modalities that offer deeper biological insights.
Market expansion is further sustained by growing investments and funding for genomic research, which provide the necessary capital for infrastructure upgrades and large-scale transcriptomics initiatives. Both public and private entities are directing substantial resources toward establishing advanced data centers and sequencing facilities to speed up drug discovery pipelines. For example, the Novo Nordisk Foundation announced in March 2024, via the 'Gefion: New AI supercomputer in Denmark' release, a commitment of approximately DKK 600 million to build a supercomputer tailored for handling massive genomic datasets. This financial support lowers entry barriers for institutions adopting next-generation sequencing workflows and correlates with high-throughput instrument uptake; Illumina's 'Fourth Quarter and Fiscal Year 2023 Results' in February 2024 confirmed the shipment of 352 NovaSeq X instruments, underscoring the global physical expansion of sequencing capacity.
Market Challenge
The Global NGS-Based RNA-Sequencing Market faces a major hurdle concerning data management and bioinformatics analysis. As sequencing technologies yield exponentially larger datasets, the ability to efficiently store, process, and interpret this information has lagged, resulting in a severe computational bottleneck. This disparity complicates workflows and significantly increases operational costs, often prolonging the time needed to extract actionable insights from raw transcriptomic data. Consequently, the complexity of managing these massive datasets restricts the scalability of RNA sequencing within routine clinical diagnostics, where rapid turnaround times are essential for patient care.
This operational inefficiency directly impacts the market's capacity to support precision medicine and drug discovery. According to the Pistoia Alliance in 2024, 52% of life science R&D professionals identified poorly curated and low-quality datasets as the primary barrier to the effective deployment of advanced analytical tools. This statistic highlights a critical gap in data readiness that hampers the industry's ability to utilize genomic data for rigorous validation. Without streamlined bioinformatics infrastructures, the translation of transcriptomic discoveries into therapeutic applications remains inefficient, thereby limiting the broader expansion of the market.
Market Trends
The integration of Machine Learning (ML) and Artificial Intelligence (AI) is fundamentally transforming transcriptomic data interpretation by addressing the critical bioinformatics bottleneck in high-throughput workflows. By using advanced algorithms, researchers can rapidly deconvolve massive datasets to identify actionable biomarkers and predict therapeutic responses efficiently. This technological synergy is driving market adoption as diagnostic providers embed these tools into core offerings to enhance precision medicine capabilities; according to Tempus AI's 'Fourth Quarter and Full Year 2024 Results' report in February 2025, the company recorded a 30.4% year-over-year revenue increase to $693.4 million, attributed to the expansion of its AI-enabled genomics platform.
Simultaneously, the commercialization of third-generation direct RNA sequencing is facilitating the detection of native RNA modifications without cDNA conversion bias. These long-read platforms allow for real-time analysis of full-length transcripts, revealing methylation patterns and splice variants that short-read technologies often miss. This capability is expanding into clinical markets, validating the utility of direct sequencing for complex biological applications. As per Oxford Nanopore Technologies' 'Annual Results for the Year Ended 31 December 2024' announcement in March 2025, the company achieved 11% revenue growth at constant currency, driven notably by a 12% expansion in its Clinical segment.
Key Market Players
* Illumina Inc.
* Thermo Fischer Scientific Inc.
* Oxford Nanopore Technologies plc
* Agilent Technologies, Inc.
* PerkinElmer Inc
* QIAGEN N.V.
* Eurofins Scientific SE
* F. Hoffmann-La Roche Ltd
* Takara Bio Inc.
* Azenta Life Sciences
Report Scope
In this report, the Global NGS-Based RNA-Sequencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# NGS-Based RNA-Sequencing Market, By Product and Services
* RNA Sequencing Platforms and Consumables
* Sample Preparation Products
* RNA Sequencing Services
* Data Analysis
* Storage
* Management
# NGS-Based RNA-Sequencing Market, By Technology
* Sequencing By Synthesis
* Ion Semiconductor Sequencing
* Single-Molecule Real-Time Sequencing
* Nanopore Sequencing
# NGS-Based RNA-Sequencing Market, By Application
* Expression Profiling Analysis
* Small RNA Sequencing
* De Novo Transcriptome Assembly
* Variant Calling
* Transcriptome Epigenetics
# NGS-Based RNA-Sequencing Market, By End User
* Research and Academia
* Hospitals and Clinics
* Pharmaceutical and Biotechnology Companies
* Others
# NGS-Based RNA-Sequencing Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global NGS-Based RNA-Sequencing Market.
Available Customizations:
Global NGS-Based RNA-Sequencing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global NGS-Based RNA-Sequencing Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product and Services (RNA Sequencing Platforms and Consumables, Sample Preparation Products, RNA Sequencing Services, Data Analysis, Storage, Management)
5.2.2. By Technology (Sequencing By Synthesis, Ion Semiconductor Sequencing, Single-Molecule Real-Time Sequencing, Nanopore Sequencing)
5.2.3. By Application (Expression Profiling Analysis, Small RNA Sequencing, De Novo Transcriptome Assembly, Variant Calling, Transcriptome Epigenetics)
5.2.4. By End User (Research and Academia, Hospitals and Clinics, Pharmaceutical and Biotechnology Companies, Others)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. North America NGS-Based RNA-Sequencing Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product and Services
6.2.2. By Technology
6.2.3. By Application
6.2.4. By End User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States NGS-Based RNA-Sequencing Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product and Services
6.3.1.2.2. By Technology
6.3.1.2.3. By Application
6.3.1.2.4. By End User
6.3.2. Canada NGS-Based RNA-Sequencing Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product and Services
6.3.2.2.2. By Technology
6.3.2.2.3. By Application
6.3.2.2.4. By End User
6.3.3. Mexico NGS-Based RNA-Sequencing Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product and Services
6.3.3.2.2. By Technology
6.3.3.2.3. By Application
6.3.3.2.4. By End User
7. Europe NGS-Based RNA-Sequencing Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product and Services
7.2.2. By Technology
7.2.3. By Application
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany NGS-Based RNA-Sequencing Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product and Services
7.3.1.2.2. By Technology
7.3.1.2.3. By Application
7.3.1.2.4. By End User
7.3.2. France NGS-Based RNA-Sequencing Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product and Services
7.3.2.2.2. By Technology
7.3.2.2.3. By Application
7.3.2.2.4. By End User
7.3.3. United Kingdom NGS-Based RNA-Sequencing Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product and Services
7.3.3.2.2. By Technology
7.3.3.2.3. By Application
7.3.3.2.4. By End User
7.3.4. Italy NGS-Based RNA-Sequencing Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product and Services
7.3.4.2.2. By Technology
7.3.4.2.3. By Application
7.3.4.2.4. By End User
7.3.5. Spain NGS-Based RNA-Sequencing Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product and Services
7.3.5.2.2. By Technology
7.3.5.2.3. By Application
7.3.5.2.4. By End User
8. Asia Pacific NGS-Based RNA-Sequencing Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product and Services
8.2.2. By Technology
8.2.3. By Application
8.2.4. By End User
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China NGS-Based RNA-Sequencing Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product and Services
8.3.1.2.2. By Technology
8.3.1.2.3. By Application
8.3.1.2.4. By End User
8.3.2. India NGS-Based RNA-Sequencing Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product and Services
8.3.2.2.2. By Technology
8.3.2.2.3. By Application
8.3.2.2.4. By End User
8.3.3. Japan NGS-Based RNA-Sequencing Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product and Services
8.3.3.2.2. By Technology
8.3.3.2.3. By Application
8.3.3.2.4. By End User
8.3.4. South Korea NGS-Based RNA-Sequencing Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product and Services
8.3.4.2.2. By Technology
8.3.4.2.3. By Application
8.3.4.2.4. By End User
8.3.5. Australia NGS-Based RNA-Sequencing Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product and Services
8.3.5.2.2. By Technology
8.3.5.2.3. By Application
8.3.5.2.4. By End User
9. Middle East & Africa NGS-Based RNA-Sequencing Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product and Services
9.2.2. By Technology
9.2.3. By Application
9.2.4. By End User
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia NGS-Based RNA-Sequencing Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product and Services
9.3.1.2.2. By Technology
9.3.1.2.3. By Application
9.3.1.2.4. By End User
9.3.2. UAE NGS-Based RNA-Sequencing Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product and Services
9.3.2.2.2. By Technology
9.3.2.2.3. By Application
9.3.2.2.4. By End User
9.3.3. South Africa NGS-Based RNA-Sequencing Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product and Services
9.3.3.2.2. By Technology
9.3.3.2.3. By Application
9.3.3.2.4. By End User
10. South America NGS-Based RNA-Sequencing Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product and Services
10.2.2. By Technology
10.2.3. By Application
10.2.4. By End User
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil NGS-Based RNA-Sequencing Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product and Services
10.3.1.2.2. By Technology
10.3.1.2.3. By Application
10.3.1.2.4. By End User
10.3.2. Colombia NGS-Based RNA-Sequencing Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product and Services
10.3.2.2.2. By Technology
10.3.2.2.3. By Application
10.3.2.2.4. By End User
10.3.3. Argentina NGS-Based RNA-Sequencing Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product and Services
10.3.3.2.2. By Technology
10.3.3.2.3. By Application
10.3.3.2.4. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global NGS-Based RNA-Sequencing Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Illumina Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Thermo Fischer Scientific Inc.
15.3. Oxford Nanopore Technologies plc
15.4. Agilent Technologies, Inc.
15.5. PerkinElmer Inc
15.6. QIAGEN N.V.
15.7. Eurofins Scientific SE
15.8. F. Hoffmann-La Roche Ltd
15.9. Takara Bio Inc.
15.10. Azenta Life Sciences
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們